Literature DB >> 19066345

Short-term effects of bicarbonate/lactate-buffered and conventional lactate-buffered dialysis solutions on peritoneal ultrafiltration: a comparative crossover study.

Jernej Pajek1, Radoslav Kveder, Andrej Bren, Andrej Gucek, Maja Bucar, Andrej Skoberne, Jacek Waniewski, Bengt Lindholm.   

Abstract

BACKGROUND: This study was designed to compare the effects of a conventional lactate-based peritoneal dialysis (PD) solution (D) and a new biocompatible bicarbonate/lactate-based solution with a low concentration of glucose degradation products (P) on peritoneal ultrafiltration (UF) and other peritoneal membrane indices.
METHODS: Twenty-six stable, prevalent PD patients were enrolled in this prospective study. They sequentially underwent 3 months of therapy with the D solution and 3 months with the P solution in a randomized order. Daily, overnight and 4-h UF on PET were measured and other peritoneal membrane indices were also assessed using PET with 2.27% glucose solution.
RESULTS: Twenty-one patients successfully completed the study. The mean daily peritoneal UF with D was 1324 +/- 602 ml and 881 +/- 633 ml with P (P < 0.001) and this lower daily UF of 443 ml (95% CI 275-610 ml) with P was associated with a similarly lower daily total fluid removal of 394 ml (95% CI 210-577 ml), as urine volume did not differ between D and P. The decrement in UF with the P solution was reversible. There were no significant differences in other peritoneal membrane indices (D/P creatinine, D/D0 glucose, 4-h UF at PET, weekly creatinine clearance, weekly urea Kt/V) or blood pressure and body weight between the solutions whereas calculated peritoneal fluid absorption rate was significantly higher with the P than with the D solution.
CONCLUSION: This study shows that the daily UF with the P solution may be lower than with the D solution. The mechanism for this short-term and reversible effect that conceivably reflects differences in biocompatibility is not clear although our results implicate that the peritoneal fluid absorption rate may differ between the two solutions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19066345     DOI: 10.1093/ndt/gfn673

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  12 in total

1.  Balance about balANZ.

Authors:  Peter G Blake
Journal:  Perit Dial Int       Date:  2012 Sep-Oct       Impact factor: 1.756

Review 2.  An update on peritoneal dialysis solutions.

Authors:  Elvia García-López; Bengt Lindholm; Simon Davies
Journal:  Nat Rev Nephrol       Date:  2012-02-21       Impact factor: 28.314

3.  The impact of dialysis solution biocompatibility on ultrafiltration and on free water transport in rats.

Authors:  Gaëlle Aubertin; Philippe Choquet; Céline Dheu; André Constantinesco; Charline Ratomponirina; Ariane Zaloszyc; Jutta Passlick-Deetjen; Michel Fischbach
Journal:  Pediatr Nephrol       Date:  2011-07-09       Impact factor: 3.714

4.  A study of the clinical and biochemical profile of peritoneal dialysis fluid low in glucose degradation products.

Authors:  Kar Neng Lai; Man Fai Lam; Joseph C K Leung; Loretta Y Chan; Christopher W K Lam; Iris H S Chan; Hoi Wong Chan; Chun Sang Li; Sunny S H Wong; Yiu Wing Ho; Au Cheuk; Matthew K L Tong; Sydney C W Tang
Journal:  Perit Dial Int       Date:  2011-11-03       Impact factor: 1.756

5.  Utility of Urinary Biomarkers in Predicting Loss of Residual Renal Function: The balANZ Trial.

Authors:  Yeoungjee Cho; David W Johnson; David A Vesey; Carmel M Hawley; Margaret Clarke; Nicholas Topley
Journal:  Perit Dial Int       Date:  2014-04-07       Impact factor: 1.756

Review 6.  Advances in Understanding and Management of Residual Renal Function in Patients with Chronic Kidney Disease.

Authors:  Xin Liu; Chunsun Dai
Journal:  Kidney Dis (Basel)       Date:  2016-09-07

7.  Biocompatibility of peritoneal dialysis solutions determined by genomics of human leucocytes: a cross-over study.

Authors:  Julia Wilflingseder; Paul Perco; Alexander Kainz; Christoph Schwarz; Reka Korbély; Bernd Mayer; Rainer Oberbauer
Journal:  NDT Plus       Date:  2009-12

8.  Strategies for preserving residual renal function in peritoneal dialysis patients.

Authors:  Arkom Nongnuch; Montira Assanatham; Kwanpeemai Panorchan; Andrew Davenport
Journal:  Clin Kidney J       Date:  2015-01-13

9.  Biocompatible peritoneal dialysis fluids: clinical outcomes.

Authors:  Yeoungjee Cho; Sunil V Badve; Carmel M Hawley; Kathryn Wiggins; David W Johnson
Journal:  Int J Nephrol       Date:  2012-11-28

10.  Biocompatible dialysis fluids for peritoneal dialysis.

Authors:  Htay Htay; David W Johnson; Kathryn J Wiggins; Sunil V Badve; Jonathan C Craig; Giovanni Fm Strippoli; Yeoungjee Cho
Journal:  Cochrane Database Syst Rev       Date:  2018-10-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.